Equities research analysts at Evercore ISI assumed coverage on shares of Polarityte (NASDAQ:PTE) in a research report issued on Wednesday, The Fly reports. The firm set an “outperform” rating on the stock.

Several other equities analysts have also issued reports on PTE. Zacks Investment Research lowered Polarityte from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. Cantor Fitzgerald set a $65.00 target price on Polarityte and gave the stock a “buy” rating in a research note on Tuesday. Piper Jaffray Companies set a $30.00 target price on Polarityte and gave the stock a “buy” rating in a research note on Monday. Finally, Northland Securities reissued a “buy” rating and set a $50.00 target price on shares of Polarityte in a research note on Monday. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $36.00.

PTE traded down $0.44 on Wednesday, reaching $12.08. The company had a trading volume of 538,217 shares, compared to its average volume of 310,156. Polarityte has a fifty-two week low of $11.54 and a fifty-two week high of $41.22. The firm has a market cap of $282.58 million, a P/E ratio of -2.49 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 13.76 and a current ratio of 13.80.

Polarityte (NASDAQ:PTE) last announced its quarterly earnings results on Monday, January 14th. The company reported ($0.96) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.02) by $0.06. Polarityte had a negative net margin of 4,259.44% and a negative return on equity of 258.52%. The business had revenue of $1.13 million for the quarter, compared to analyst estimates of $0.80 million. As a group, equities analysts forecast that Polarityte will post -4.11 earnings per share for the current year.

Polarityte Company Profile

PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.

Read More: What does the Producer Price Index (PPI) tell investors?

The Fly

Analyst Recommendations for Polarityte (NASDAQ:PTE)

Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.